It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Safety and tolerability of fixed antihypertensive combinations in bloo
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14844

Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination



Review

(4747) Total Article Views


Authors: Ijlal Uddin, Shakil Aslam

Published Date November 2010 Volume 2010:3 Pages 155 - 162
DOI: http://dx.doi.org/10.2147/IBPC.S6662

Ijlal Uddin, Shakil Aslam
Division of Nephrology and Hypertension, Georgetown University Hospital, Washington, District of Columbia, USA

Abstract: Hypertension is a major health problem worldwide and remains underdiagnosed and undertreated. Although public awareness and control of hypertension have improved over the last decade, only one-third of hypertensive patients achieve the rather conservative blood pressure (BP) goal of <140/90 mmHg. Most hypertensive patients require more than one drug for optimum BP control. Expert panels recommend use of combination therapy with two or more medications for Stage 2 and higher hypertension and in high-risk patients. However, the use of multiple drugs reduces patient compliance. Fixed-dose combination therapy helps improve patient compliance and thus achieve the target BP. Dose titration of the individual constituent drugs is recommended before switching to an equivalent fixed-dose combination. Randomized, controlled trials have shown that the fixed-dose combination of amlodipine–olmesartan medoxomil is more effective in lowering BP than monotherapy with either of these agents, with a similar side effect profile.

Keywords: hypertension, target blood pressure, compliance, amlodipine, olmesartan


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • ACC 2014

    We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.